# Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

> **NCT02096458** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 8 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease
- Erosive Esophagitis
- Heartburn

## Interventions

- **DRUG:** Dexlansoprazole

## Key facts

- **NCT ID:** NCT02096458
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096458, "Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02096458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*